申请人:Genentech, Inc.
公开号:US20150368244A1
公开(公告)日:2015-12-24
The invention relates to 1,5-diazacarbazole compounds of Formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) and (I-h) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
该发明涉及一种具有式(I)、(I-a)、(I-b)、(I-c)、(I-d)、(I-e)、(I-f)、(I-g)和(I-h)的1,5-二氮杂咔唑化合物,这些化合物可用作激酶抑制剂,更具体地用作检查点激酶1(chk1)抑制剂,因此可用作癌症治疗药物。该发明还涉及组合物,更具体地涉及包含这些化合物的制药组合物以及使用这些组合物治疗各种癌症和过度增殖性疾病的方法,以及使用这些化合物进行体外、体内和体内诊断或治疗哺乳动物细胞或相关病理条件的方法。